QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Organovo Stock Price, News & Analysis (NASDAQ:ONVO)

$1.18
0.00 (0.00%)
(As of 11/28/2023 ET)
Compare
Today's Range
$1.16
$1.20
50-Day Range
$1.05
$1.84
52-Week Range
$1.00
$3.40
Volume
28,024 shs
Average Volume
76,325 shs
Market Capitalization
$10.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Organovo MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
5.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Organovo in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$31,763 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.75) to ($1.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.23 out of 5 stars

Medical Sector

921st out of 949 stocks

Biological Products, Except Diagnostic Industry

158th out of 160 stocks


ONVO stock logo

About Organovo Stock (NASDAQ:ONVO)

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

ONVO Stock Price History

ONVO Stock News Headlines

StockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
ONVO, FATH and BYU among mid-day movers
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
ONVO Organovo Holdings, Inc.
Organovo (NASDAQ: ONVO)
Organovo Announces FXR Program
Organovo Holdings, Inc. (ONVO)
See More Headlines
Receive ONVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2019
Today
11/28/2023
Next Earnings (Estimated)
2/08/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONVO
Fax
N/A
Employees
23
Year Founded
N/A

Profitability

Net Income
$-17,260,000.00
Net Margins
-4,061.12%
Pretax Margin
-5,093.21%

Debt

Sales & Book Value

Annual Sales
$368,000.00
Book Value
$1.76 per share

Miscellaneous

Free Float
8,284,000
Market Cap
$10.29 million
Optionable
Optionable
Beta
0.84
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Keith E. Murphy (Age 51)
    Company Secretary & Executive Chairman
    Comp: $626.24k
  • Ms. Vaidehi Joshi (Age 36)
    Director of Discovery Biology & Director
    Comp: $91.4k
  • Mr. Thomas P. Hess CPA (Age 59)
    MBA, President & CFO
  • Dr. Curtis M. Tyree Ph.D.
    Senior Vice President of Strategy & Business Development














ONVO Stock Analysis - Frequently Asked Questions

How have ONVO shares performed in 2023?

Organovo's stock was trading at $1.41 at the beginning of the year. Since then, ONVO stock has decreased by 16.3% and is now trading at $1.18.
View the best growth stocks for 2023 here
.

When is Organovo's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our ONVO earnings forecast
.

How were Organovo's earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) announced its earnings results on Thursday, August, 8th. The medical research company reported ($1.00) EPS for the quarter, hitting the consensus estimate of ($1.00). The medical research company earned $0.67 million during the quarter, compared to the consensus estimate of $0.77 million. Organovo had a negative trailing twelve-month return on equity of 129.61% and a negative net margin of 4,061.12%.

When did Organovo's stock split?

Organovo shares reverse split on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Taylor Crouch's approval rating as Organovo's CEO?

3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Organovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK).

Who are Organovo's major shareholders?

Organovo's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Gobel and Douglas Jay Cohen.
View institutional ownership trends
.

How do I buy shares of Organovo?

Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ONVO) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -